The broad eligibility picture

Many people arrive at a cartilage specialist expecting to be told the damage is too advanced, too widespread, or that they are simply too old. In practice, the eligibility threshold for ChondroFiller injection is considerably broader than most patients anticipate.

Any adult with cartilage wear visible on MRI or other imaging may be considered — regardless of whether the damage is a single contained focal defect or diffuse wear spread across the joint surface. No upper age limit applies to the injectable pathway, and unlike some surgical cartilage repair procedures, there is no defect-size ceiling for the injectable collagen scaffold form.

The treatment is used across eight joints: knee, hip, shoulder, ankle, elbow, foot, hand, and wrist. If your joint appears on that list and imaging has confirmed cartilage loss, a specialist assessment is the appropriate next step rather than immediate self-exclusion.

The injection is also specifically positioned as a joint-preservation pathway for active patients in their 60s and 70s who have been advised that joint replacement is the logical next move. A 'bone on bone' appearance on imaging is not an automatic disqualifier; specialist guidance consistently frames it as a prompt for assessment, not dismissal.

Clinical profiles most likely to be assessed

Three clinical presentations emerge consistently as strong starting points for an assessment conversation.

Cartilage damage confirmed on imaging

The primary entry criterion is structural damage visible on MRI — whether a single focal defect or wear spread more diffusely across the joint surface. Grade III or IV chondral changes are typical targets, and patients who have not yet had formal imaging are usually referred for an MRI before suitability can be confirmed.

Post-traumatic chondral injury

Cartilage damage following a specific event — such as a meniscal tear, ligament reconstruction, or a diagnosis of osteochondritis dissecans (OCD) — forms a distinct candidacy group. This category spans a wide age range; younger adults and athletes managing the after-effects of a sports injury fit the profile just as clearly as older patients with accumulated joint wear.

Active patients who have reached the limits of conservative management

Patients who have pursued physiotherapy, oral analgesics, or standard corticosteroid or viscosupplementation injections without adequate or lasting relief — and who are now being advised that joint replacement is the logical next step — are among those for whom the injectable scaffold pathway was specifically designed. The goal is supporting the body's own repair processes to preserve the joint rather than replacing it.

Imaging confirms the starting point, but mechanical joint stability must also be evaluated before a treatment plan can be agreed.

The mechanical stability prerequisite

Cartilage wear rarely happens in a vacuum. Before proceeding with a ChondroFiller injection, the treating clinician will assess the joint's mechanical environment — because placing a regenerative scaffold in a joint that remains mechanically unsound is, in practical terms, like repainting a wall without fixing the underlying leak.

Three factors are evaluated: ligament integrity, overall joint alignment, and the condition of load-distributing structures such as the menisci in the knee. Where significant instability, malalignment, or an active structural deficit is actively driving continued cartilage loss, that problem must be addressed first or in parallel. The injectable collagen scaffold promotes endogenous repair at the articular surface; it does not alter the mechanical forces acting on the joint from outside that surface.

This prerequisite applies across all eight treatable joints, not just the knee. In the ankle, for example, persistent malalignment — where the joint tracks unevenly under load — would continue to stress the cartilage surface regardless of scaffold placement. Correcting the alignment first, through whatever approach the clinician determines appropriate, protects the repair environment and gives the scaffold a realistic chance to work.

Where a mechanical issue is identified, the consultation will clarify whether it needs to be resolved before the injection, or whether both can be managed together within a single clinical plan.

Absolute contraindications

Three clinical factors represent absolute barriers to proceeding with a ChondroFiller injection, regardless of which joint is involved.

• Active infection — any confirmed local or systemic infection must be resolved before injection. Introducing a scaffold into an infected joint carries significant risk, and the joint must be demonstrably infection-free before candidacy can be confirmed.
• Immunosuppression — patients on immunosuppressive medication, or with conditions that substantially impair immune function, are not suitable. The scaffold's repair mechanism depends on the body's own cell-recruitment capacity, which immunosuppression may compromise.
• Poorly controlled diabetes — metabolic instability affects tissue healing and infection risk; adequate glycaemic control is a prerequisite.

These three exclusions apply consistently across all eight treatable joints. There is no joint-specific exception to the infection or immunosuppression rules.

Separate from these clinical barriers is the question of expectations. Because the scaffold works by recruiting the patient's own progenitor cells over weeks to months, meaningful improvement is not immediate. Clinicians discuss this timeline at consultation — not as a warning against the treatment, but as an accurate picture of how acellular matrix-induced chondrogenesis works. For most adults presenting with cartilage damage, none of the above exclusions will apply.

How candidacy shifts when a second injection or different pathway is also discussed

Most assessment conversations are straightforward: imaging confirms damage, the joint is mechanically stable, and the injectable collagen scaffold pathway is the natural next step. Two clinical situations introduce additional considerations.

When the defect is focal and the surrounding joint is otherwise healthy

Where imaging reveals a single, well-contained cartilage defect with healthy surrounding tissue, a clinician may introduce a second option at consultation: the Liquid Cartilage™ keyhole procedure. Both approaches use the same scaffold material; what differs is the clinical setting and delivery method. The injectable route is an ultrasound-guided outpatient procedure; the alternative involves arthroscopic placement in a dry joint environment. Neither pathway is automatic — the consultation after imaging review determines which better fits the specific defect characteristics.

When the knee is both worn and actively inflamed

For patients whose knee shows cartilage loss alongside reactive change — persistent synovial inflammation or an effusion linked to osteoarthritis — a combined approach known as CFI+ may be discussed. This pairs the ChondroFiller injection with Arthrosamid, a permanent non-regenerative polyacrylamide hydrogel that addresses joint-space symptoms through an entirely distinct mechanism. The two products are not variations of the same treatment and should not be conflated: ChondroFiller is a regenerative scaffold; Arthrosamid is a permanent hydrogel filler. Arthrosamid is not added simply because swelling is present — it requires its own independent clinical justification.

For non-knee joints, evidence draws largely on smaller single-centre or manufacturer-supported studies rather than large randomised trials. A clinician will weigh that openly during the assessment conversation, factoring it into any combined or alternative pathway discussion.

Getting a candidacy assessment

Confirming suitability for ChondroFiller injection requires a structured clinical assessment — an imaging report alone is not enough to establish it. A consultant will typically work across three areas: the scan findings (defect location, depth, and grade across whichever joint or joints are involved); mechanical joint status (alignment, ligament integrity, and whether any concurrent pathology needs addressing before or alongside the scaffold pathway); and the patient's medical background, covering infection risk, immune status, glycaemic control where relevant, and personal treatment goals.

If a recent MRI of the affected joint is not already available, arranging one before consultation is the most useful practical step a patient can take in preparation.

Specialists who offer ChondroFiller as an outpatient, ultrasound-guided injectable pathway are available across the UK. Search MSK allows patients to filter by region and treatment type to identify clinicians who offer this pathway near them. What the assessment itself then establishes is not simply a binary answer, but a specific clinical rationale — which joint, which defect pattern, which delivery approach, and what a realistic biological timeline looks like for that individual.